Table 8 Commercially available stents coated with biodegradable polymers
From: Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach
Stent | Platform | Drug | Strut thickness (µm) | Polymer | Coating thickness (µm) | Degradation time (months) | Rate of drug release |
|---|---|---|---|---|---|---|---|
Biomatrix alpha (Biosensors) | CoCr | Biolimus | 88–84 | PLLA | 10 | 6–9 | 60% in 90 days |
Ultimaster (Terumo) | CoCr | Sirolimus | 80 | PDLLA-PCL | 15 | 3–4 | 90% in 90 days |
Yukon Choice PC (Translumina) | 316L | Sirolimus | 87 | PDLLA | 5 | 6–9 | More than 80% in 30 days |
Synergy (Boston Scientific) | PtCr | Everolimus | 74–81 | PLGA | 4 | 4 | 50% in 30 days |
Orsiro (Biotronik) | CoCr | Sirolimus | 60–80 | PLLA | 7 | 14 | 50% in 30 days |